强化与标准伐尼克兰戒烟治疗的经济学评价
该经济学评价基于QUITS随机试验的1251名吸烟者,比较12周或24周伐尼克兰单药、12周或24周伐尼克兰联合尼古丁替代贴剂的戒烟效果与成本。52周戒断率各组相近(23.6%–25.1%),12周单药总平均成本最低(1175美元),其增量成本效果比为每增加1名戒烟者4681美元、每增加1个质量调整生命年4579美元。24周联合方案相对于12周单药的增量成本效果比高达每增加1名戒烟者9200万美元、每增加1个质量调整生命年9000万美元(95%CI 15703美元至被支配或更贵且效果更差)。作者认为12周伐尼克兰单药在常用阈值10万美元/质量调整生命年下最具成本效果。
要点
- 52周戒断率:12周单药25.1%(79/315)、24周单药24.4%(76/311)、12周联合23.6%(74/314)、24周联合25.1%(78/311)。
- 总平均成本:12周单药1175美元、12周联合1374美元、24周单药2022美元、24周联合2118美元。
- 12周伐尼克兰单药的增量成本效果比为每增加1名戒烟者4681美元、每增加1个质量调整生命年4579美元。
- 24周联合方案相对于12周单药的增量成本效果比为每增加1名戒烟者9200万美元、每增加1个质量调整生命年9000万美元(95%CI 15703美元至被支配或更贵且效果更差)。
- 作者认为在常用阈值10万美元/质量调整生命年下,12周伐尼克兰单药是最具成本效果的选项。
适用人群与场景
- 试图戒烟的吸烟个体,来源于QUITS随机试验的1251名参与者,于2017年11月11日至2020年7月2日在威斯康星州麦迪逊和密尔沃基入组。
诊断标准与关键阈值
- 7天时点戒断率,通过呼出气一氧化碳水平≤5 ppm进行生化确认,在52周时评估。
处置流程与药物剂量
- 12周伐尼克兰单药治疗(n=315)。
- 24周伐尼克兰单药治疗(n=311)。
- 12周伐尼克兰联合尼古丁替代贴剂治疗(n=314)。
- 24周伐尼克兰联合尼古丁替代贴剂治疗(n=311)。
研究设计与关键结果
- 经济评价基于QUITS随机试验,纳入1251名吸烟者,随机分为4组:12周伐尼克兰单药(n=315)、24周伐尼克兰单药(n=311)、12周伐尼克兰联合尼古丁替代贴剂(n=314)、24周伐尼克兰联合尼古丁替代贴剂(n=311)。
- 参与者平均(SD)年龄49.1(11.9)岁,675名(54.0%)为女性,881名(70.4%)完成52周随访。
- 52周戒断率:12周单药25.1%(79/315)、24周单药24.4%(76/311)、12周联合23.6%(74/314)、24周联合25.1%(78/311)。
- 总平均(SD)成本:12周单药1175(365)美元、12周联合1374(412)美元、24周单药2022(813)美元、24周联合2118(1058)美元。
- 12周伐尼克兰单药的增量成本效果比为每增加1名戒烟者4681美元、每增加1个质量调整生命年4579美元。
- 24周联合方案相对于12周单药的增量成本效果比为每增加1名戒烟者9200万美元、每增加1个质量调整生命年9000万美元(95%CI 15703美元至被支配或更贵且效果更差)。
证据类型、等级与局限
- 证据类型:基于随机对照试验(QUITS)的经济学评价。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该经济学评价提示,在常用阈值10万美元/质量调整生命年下,12周伐尼克兰单药是最具成本效果的戒烟治疗选项,可帮助患者、医疗专业人员和其他利益相关者理解更强化的伐尼克兰治疗方案的卫生经济学影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Smoking is the leading preventable cause of death and illness in the US. Identifying cost-effective smoking cessation treatment may increase the likelihood that health systems deliver such treatment to their patients who smoke.
OBJECTIVE: To evaluate the cost-effectiveness of standard vs enhanced varenicline use (extended varenicline treatment or varenicline in combination with nicotine replacement therapy) among individuals trying to quit smoking.
DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation assesses the Quitting Using Intensive Treatments Study (QUITS), which randomized 1251 study participants who smoked into 4 conditions: (1) 12-week varenicline monotherapy (n = 315); (2) 24-week varenicline monotherapy (n = 311); (3) 12-week varenicline combination treatment with nicotine replacement therapy patch (n = 314); or (4) 24-week varenicline combination treatment with nicotine replacement therapy patch (n = 311). Study enrollment occurred in Madison and Milwaukee, Wisconsin, between November 11, 2017, and July 2, 2020. Statistical analysis took place from May to October 2023.
MAIN OUTCOMES AND MEASURES: The primary outcome was 7-day point prevalence abstinence (biochemically confirmed with exhaled carbon monoxide level ≤5 ppm) at 52 weeks. The incremental cost-effectiveness ratio (ICER), or cost per additional person who quit smoking, was calculated using decision tree analysis based on abstinence and cost for each arm of the trial.
RESULTS: Of the 1251 participants, mean (SD) age was 49.1 (11.9) years, 675 (54.0%) were women, and 881 (70.4%) completed the 52-week follow-up. Tobacco cessation at 52 weeks was 25.1% (79 of 315) for 12-week monotherapy, 24.4% (76 of 311) for 24-week monotherapy, 23.6% (74 of 314) for 12-week combination therapy, and 25.1% (78 of 311) for 24-week combination therapy, respectively. The total mean (SD) cost was $1175 ($365) for 12-week monotherapy, $1374 ($412) for 12-week combination therapy, $2022 ($813) for 24-week monotherapy, and $2118 ($1058) for 24-week combination therapy. The ICER for 12-week varenicline monotherapy was $4681 per individual who quit smoking and $4579 per quality-adjusted life-year (QALY) added. The ICER for 24-week varenicline combination therapy relative to 12-week monotherapy was $92 000 000 per additional individual who quit smoking and $90 000 000 (95% CI, $15 703 to dominated or more costly and less efficacious) per additional QALY.
CONCLUSIONS AND RELEVANCE: This economic evaluation of standard vs enhanced varenicline treatment for smoking cessation suggests that 12-week varenicline monotherapy was the most cost-effective treatment option at the commonly cited threshold of $100 000/QALY. This study provides patients, health care professionals, and other stakeholders with increased understanding of the health and economic impact of more intensive varenicline treatment options.
参考来源
- Mundt MP, Stein JH, Fiore MC, et al. Economic Evaluation of Enhanced vs Standard Varenicline Treatment for Tobacco Cessation. JAMA Netw Open. 2024. PMID: 38683609. doi:10.1001/jamanetworkopen.2024.8727
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。